(4S)-(E)-7-<4-<4-<<(4-cyclohexylbutyl)amino>carbonyl>-4,5-dihydro-2-oxazolyl>phenyl>-7-(3-pyridyl)hept-6-enoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-(E)-7-<4-<4-<<(4-cyclohexylbutyl)amino>carbonyl>-4,5-dihydro-2-oxazolyl>phenyl>-7-(3-pyridyl)hept-6-enoic acid
• 英文别名: (4S)-(E)-7-[4-[4-[[(4-Cyclohexylbutyl)amino]carbonyl]-4,5-dihydro-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic Acid；(E)-7-[4-[(4S)-4-(4-cyclohexylbutylcarbamoyl)-4,5-dihydro-1,3-oxazol-2-yl]phenyl]-7-pyridin-3-ylhept-6-enoic acid
• 化学式: C₃₂H₄₁N₃O₄
• 分子量: 531.695
• InChiKey: LTCQRNQPODCPAS-IMDLGZNOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  39
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  对苯二甲醇 在 N-甲基吗啉 、 咪唑 、 四氯化碳 、 manganese(IV) oxide 、 sodium hydroxide 、 jones reagent 、 potassium tert-butylate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 、 乙腈 为溶剂， 生成 (4S)-(E)-7-<4-<4-<<(4-cyclohexylbutyl)amino>carbonyl>-4,5-dihydro-2-oxazolyl>phenyl>-7-(3-pyridyl)hept-6-enoic acid
  参考文献：
  名称：

  Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives

  摘要：

  Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00353-9

文献信息

• Preparation of substituted alkenoic acids
  申请人：Eli Lilly and Company

  公开号：US05849922A1

  公开（公告）日：1998-12-15

  This invention relates to a highly selective process for preparation of E-.omega.-phenyl-.omega.-(3-pyridyl)-.omega.-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

  本发明涉及一种高度选择性的过程，用于制备在苯环上带有氨基甲酰基取代的噁唑基或噁唑啉基的E-ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物，这些衍生物表现出对血栓素受体拮抗和/或血栓素合酶抑制作用的用途，以及用于制备这些衍生物的中间体。
• Intermediates in the preparation of substituted alkenoic acids
  申请人：Eli Lilly and Company

  公开号：US06031095A1

  公开（公告）日：2000-02-29

  This invention relates to a highly selective process for preparation of E-.omega.-phenyl-.omega.-(3-pyridyl)-.omega.-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

  本发明涉及一种高度选择性的制备E-.omega.-苯基-.omega.-(3-吡啶基)-.omega.-烯酸衍生物的方法，其中苯环上带有一个氨基甲酰取代的噁唑基或噁唑啉基，该方法对于血栓素受体拮抗和/或血栓素合酶抑制具有实用性，同时还涉及其中间体。
• Carbamoyl substituted heterocycles
  申请人：Eli Lilly and Company

  公开号：US06075147A1

  公开（公告）日：2000-06-13

  This invention relates to carbamoyl substituted heterocycles which are .omega.-phenyl-.omega.-(3-pyridyl)-.omega.-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

  本发明涉及一种含有氨基甲酰取代杂环的化合物，其为ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物，苯环上带有氨基甲酰取代的噁唑基或噁唑烷基，具有治疗血栓素受体拮抗和/或血栓素合酶抑制作用的实用性，以及含有它们的制药配方、使用它们的方法以及它们的制备过程和中间体。
• Carbamoly substituted heterocycles
  申请人：Eli Lilly and Company

  公开号：US06114534A1

  公开（公告）日：2000-09-05

  This invention relates to carbamoyl substituted heterocycles which are .omega.-phenyl-.omega.-(3-pyridyl)-.omega.-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

  本发明涉及氨基甲酰取代的杂环，其为ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物，在苯环上带有氨基甲酰取代的噁唑基或噁唑啉基，并且展示了用于抗血栓素受体拮抗和/或抗血栓素合成酶抑制的效用，以及含有它们的制药配方、它们的使用方法以及它们的制备过程和中间体。
• Carbamoyl substituted oxazoles as thromboxane receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0811621A2

  公开（公告）日：1997-12-10

  This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

  本发明涉及氨基甲酰基取代的杂环，这些杂环是ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物，在苯基环上带有氨基甲酰基取代的噁唑基或噁唑啉基，具有血栓素受体拮抗和/或血栓素合成酶抑制作用，还涉及含有这些杂环的药物制剂、使用方法以及制备这些杂环的工艺和中间体。